Company: TVRD
Filing Date: 2025-05-13
Form Type: 8-K
Source: 0001104659-25-047856
Chunk: 1

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-13
Form: 8-K
Item: Item 2.02
Chunk 1
---
 or procedure, which disagreements,
if not resolved to the satisfaction of EY, would have caused EY to make reference to the subject matter of such disagreements in connection
with its reports on the consolidated financial statements for such periods and (2) there were no “reportable events” (as defined
in Item 304(a)(1)(v) of Regulation S-K).

The Company
provided EY with a copy of this report prior to its filing with the SEC and requested that EY furnish the Company with a letter addressed
to the SEC stating whether EY agrees with the statements made by the Company in this report and, if not, stating the respects, if any,
in which EY does not agree with such statements. A copy of the letter from EY is filed with this Current Report on Form 8-K as Exhibit
16.1.

(b)
Engagement of New Independent Registered Public Accounting Firm

On May 12,
2025, the Audit Committee approved Deloitte & Touche LLP (“ Deloitte”) as the Company’s independent registered public
accounting firm for the fiscal year ending December 31, 2025. On May 13, 2025, Deloitte was engaged as the Company’s independent
registered public accounting firm. Deloitte served as the independent registered public accounting firm of Legacy Tvardi prior to the
consummation of the merger of Legacy Tvardi with the Delaware corporation formerly known as “ Cara Therapeutics, Inc.”

During the
Company’s fiscal years ended December 31, 2024 and 2023, and the subsequent interim period through May 13, 2025, neither the Company
nor anyone acting on its behalf consulted with Deloitte regarding: (i) the application of accounting principles to a specified transaction,
either completed or proposed; or the type of audit opinion that might be rendered on the Company’s financial statements, and neither
a written report nor oral advice was provided to the Company that Deloitte concluded was an important factor considered by the Company
in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of
a “disagreement” within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 or a
“reportable event” within the meaning of Item 304(a)(1)(v) of Regulation S-K.

Item 9.01. Financial Statements